echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Express HPV-positive refractory tumor patients have improved their survival by more than 4 times, and the results of phase 2 clinical studies of triple therapy are positive

    Express HPV-positive refractory tumor patients have improved their survival by more than 4 times, and the results of phase 2 clinical studies of triple therapy are positive

    • Last Update: 2022-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ▎WuXi AppTec content team editor recently, PDS Biotechnology has published interim data
    from an expanded Phase 2 clinical trial of an investigational triple therapy for advanced human papillomavirus (HPV)-positive cancer, including its lead drug candidate, PDS0101.

    Each year, about 43,000 patients are diagnosed with HPV-related cancer
    .
    Both men and women are affected by HPV-related cancer, but in very different
    ways.
    In women, HPV infection most commonly causes cervical,, or vulvar cancer
    .
    In men, more than 80 percent of patients have oropharyngeal cancer and can affect the head and neck
    .
    HPV-16 is the most common type of HPV in these cancers and the most virulent high-risk HPV type
    .
    Current treatments for HPV-related tumors not only have a low response rate, but also have a short
    remission period for patients.



    PDS0101 is a drug candidate developed by PDS Biotechnology using its proprietary T cell activation platform technology Versamune to combine structurally specific positively charged (cationic) lipids witha proprietary cocktail of H PV16 antigens.

    These combinations, administered by simple subcutaneous injection, have been shown to stimulate the activation
    of multiple key immune pathways associated with effective T cell induction and enhanced anticancer activity.
    Currently, PDS0101 is in a number of Phase 2 clinical studies
    .


    ▲ PDS0101's R&D pipeline (picture from PDS Biotech official website) The phase 2 clinical trial data released this time includes the interim efficacy data of 37 HPV 16-positive evaluable patients, of which 29 patients are patients in the immune checkpoint inhibitor (CPI)
    refractory group
    。 The triple therapy includes PDS0101 with two immunomodulators under investigation, M9241 (targeted delivery of IL-12) and bintrafusp alfa (PD-L1/TGF-β bifunctional checkpoint inhibitor), both from Merck KG.

    The results of the study showed that 66% (19/29) of HPV 16-positive and CPI-refractory patients were still alive at 16 months of follow-up, compared with historical data for the median overall survival of such patients of only 3-4 months
    .
    Data from HPV 16-positive CPI-naïve patients are also encouraging, with 75% (6/8) remaining alive at 25 months of follow-up and 38% (3/8) achieving complete remission (CR).

    In terms of safety, 48% (24/50) of patients experienced level 3 treatment-related adverse events (AEs), 4% (2/50) of patients experienced grade 4 AEs, and no level 5 treatment-related AEs
    were found.

    "Interim expanded data using PDS0101-based triple therapy for advanced HPV-positive cancer in a challenging patient population with few available treatment options is continuing to demonstrate the clinical efficacy, robustness, and safety of this therapy," PDS Biotechnology said Dr.
    Frank Bedu-Addo, President and Chief Executive Officer of the United States Council, said, "Importantly, these results support the continued development of this new combination for CPI-refractory patients who do not yet have approved standard care to address such significant unmet needs
    .



    WuXi AppTec provides integrated, end-to-end new drug R&D and manufacturing services to the global biopharmaceutical industry, covering chemical drug R&D and manufacturing, biological research, preclinical testing and clinical trial R&D, cell and gene therapy R&D, testing and manufacturing
    .
    If you have related business needs, please click the picture below to fill in the specific information
    .

    If you have any business needs, please long press to scan the QR code above, or
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.